Apellis Pharmaceuticals, Inc. — Director's Dealing 2018

Sep 17, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2018-09-14

Reporting Person: Watson David O. (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-09-14	Common Stock	M	32818	$2.67	Acquired	32818	Direct
2018-09-14	Common Stock	S	15776	$18.784	Disposed	17042	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-09-14	Stock Option (right to buy)	$2.67	M	32818	Disposed	2023-12-31	Common Stock (32818)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	10000	Indirect

Footnotes

F1: The price reported is a weighted average. The shares were sold in multiple transactions at prices per share ranging from $18.50 to $19.025, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc. ("Apellis"), any security holder of Apellis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The securities are held by The Watson Education Trust (the "Trust"), for which the reporting person serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.

F3: This option was granted on January 1, 2014 and has fully vested.